Trials / Conditions / Lymphoblastic Leukemia, Acute, Childhood

Lymphoblastic Leukemia, Acute, Childhood

20 registered clinical trials studyying Lymphoblastic Leukemia, Acute, Childhood — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph NCT05495035	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Unknown	Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage NCT05429905	KK Women's and Children's Hospital	Phase 1 / Phase 2
Completed	CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicit NCT05440409	National Cancer Institute (NCI)	—
Recruiting	CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic NCT05043571	National University Hospital, Singapore	Phase 1
Recruiting	ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. NCT05038696	National University Hospital, Singapore	Phase 1
Terminated	N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia NCT05611086	Teny Tjitra Sari	Phase 4
Active Not Recruiting	PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia NCT03817320	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1 / Phase 2
Completed	Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy NCT02879643	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Unknown	Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol NCT03022747	Vastra Gotaland Region	Phase 2
Completed	Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome NCT02906371	University of Pennsylvania	Phase 1
Completed	A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leuk NCT01614197	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Completed	A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL NCT01861002	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Completed	AC220 for Children With Relapsed/Refractory ALL or AML NCT01411267	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Completed	Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL NCT01896752	Rigshospitalet, Denmark	—
Completed	A Study Of Panobinostat In Children With Refractory Hematologic Malignancies NCT01321346	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Terminated	EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (A NCT01186328	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1
Terminated	Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors NCT01100658	University of Minnesota	N/A
Completed	A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine NCT00991133	Genzyme, a Sanofi Company	Phase 1
Unknown	ALL-SCT BFM International- HSCT in Children and Adolescents With ALL NCT01423500	St. Anna Kinderkrebsforschung	Phase 3
Unknown	Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia NCT01423747	St. Anna Kinderkrebsforschung	Phase 3